Compile Data Set for Download or QSAR
maximum 50k data
Found 370 Enz. Inhib. hit(s) with all data for entry = 6885
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156026(US9018214, 77)
Affinity DataIC50:  9nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156180(US9018214, 231)
Affinity DataIC50:  9.5nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156012(US9018214, 63)
Affinity DataIC50:  10nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156135(US9018214, 186)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156119(US9018214, 170)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156124(US9018214, 175)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156035(US9018214, 86)
Affinity DataIC50:  12nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156048(US9018214, 99)
Affinity DataIC50:  12nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156093(US9018214, 144)
Affinity DataIC50:  12nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156112(US9018214, 163)
Affinity DataIC50:  13nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156049(US9018214, 100)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156138(US9018214, 189)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156043(US9018214, 94)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156169(US9018214, 220)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156086(US9018214, 137)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156099(US9018214, 150)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156161(US9018214, 212)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156114(US9018214, 165)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156204(US9018214, 255)
Affinity DataIC50:  14nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156038(US9018214, 89)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156025(US9018214, 76)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156024(US9018214, 75)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156046(US9018214, 97)
Affinity DataIC50:  17nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156095(US9018214, 146)
Affinity DataIC50:  17nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156016(US9018214, 67)
Affinity DataIC50:  17nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156202(US9018214, 253)
Affinity DataIC50:  17nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156126(US9018214, 177)
Affinity DataIC50:  18nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156100(US9018214, 151)
Affinity DataIC50:  19nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156040(US9018214, 91)
Affinity DataIC50:  19nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156175(US9018214, 226)
Affinity DataIC50:  21nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156184(US9018214, 235)
Affinity DataIC50:  21nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156070(US9018214, 121)
Affinity DataIC50:  21nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156160(US9018214, 211)
Affinity DataIC50:  22nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156047(US9018214, 98)
Affinity DataIC50:  23nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156147(US9018214, 198)
Affinity DataIC50:  23nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156055(US9018214, 106)
Affinity DataIC50:  23nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156163(US9018214, 214)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156205(US9018214, 256)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156177(US9018214, 228)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156036(US9018214, 87)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156028(US9018214, 79)
Affinity DataIC50:  25nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156071(US9018214, 122)
Affinity DataIC50:  29nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156139(US9018214, 190)
Affinity DataIC50:  29nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156133(US9018214, 184)
Affinity DataIC50:  31nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156136(US9018214, 187)
Affinity DataIC50:  32nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156029(US9018214, 80)
Affinity DataIC50:  33nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156059(US9018214, 110)
Affinity DataIC50:  35nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156027(US9018214, 78)
Affinity DataIC50:  35nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156137(US9018214, 188)
Affinity DataIC50:  40nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astex Therapeutics

US Patent
LigandPNGBDBM156212(US9018214, 265)
Affinity DataIC50:  41nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domain...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 370 total ) | Next | Last >>
Jump to: